ClinicalTrials.gg
CompletedNCT01826981Updated Nov 16, 2018Results posted

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

A Phase 2 interventional study of LDV/SOF and SOF in Chronic Hepatitis C, sponsored by Gilead Sciences. Completed at 2 sites in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
359
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sofosbuvir in Hepatitis C, Chronic — none open to participants now, 1 under way, none of them phase 3. Sofosbuvir · Hepatitis C, Chronic.

Enrollment
5th of 50
359 · median 65
Started
2013
with 4 others
Phase 2
15 of 50
none open now
Registered
12th of 50
by date
Lead sponsor
13 of 50
Gilead Sciences

Among the 50 studies testing sofosbuvir in Hepatitis C, Chronic, this one is the 5th largest by enrollment, is one of 5 that started in 2013, is one of 15 in phase 2, and was the 12th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 50 studies testing sofosbuvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing sofosbuvir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the antiviral efficacy, safety, tolerability of combination therapy with sofosbuvir (SOF) containing regimens for the treatment of chronic hepatitis C virus (HCV) infection.

03

Conditions studied

  • Chronic Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic genotype 1, 2, 3, or 6 infection
  • Cirrhosis determination; a liver may be required
  • Screening laboratory values within defined thresholds
  • Use of two effective methods if female of or sexually active male

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing female or male with pregnant female partner
  • Hepatocellular carcinoma (HCC) or other (with exception of certain resolved skin cancers)
  • Chronic use of systemic agents
  • History of illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
359 participants (actual)

Study arms

  • Experimental
    Cohort 1,Group 1: LDV/SOF + RBV 12 wk (GT1 SOF retreatment)

    LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    Cohort 1,Group 2:SOF+Peg-IFN+RBV 12 wk (GT2,3 SOF retreatment)

    SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study

    Drug: SOF · Drug: RBV · Drug: Peg-IFN

  • Experimental
    Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, liver disease)

    LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    Cohort 2,Group 2: LDV/SOF+GS-9669 12wk (GT1 TE, liver disease)

    LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis

    Drug: LDV/SOF · Drug: GS-9669

  • Experimental
    Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)

    LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection

    Drug: LDV/SOF

  • Experimental
    Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)

    LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)

    LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection

    Drug: LDV/SOF

  • Experimental
    Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)

    LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    Cohort 3,Group 1: LDV/SOF 12 wk (GT1 cirrhotic CPT B)

    LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis

    Drug: LDV/SOF

  • Experimental
    Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN noncirrhotic)

    SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection

    Drug: SOF · Drug: VEL

  • Experimental
    Cohort 4,Group 2:SOF+VEL 25mg+RBV 8 wk (GT3 TN noncirrhotic)

    SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection

    Drug: SOF · Drug: RBV · Drug: VEL

  • Experimental
    Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN noncirrhotic)

    SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection

    Drug: SOF · Drug: VEL

  • Experimental
    Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN noncirrhotic)

    SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection

    Drug: SOF · Drug: RBV · Drug: VEL

  • Experimental
    Cohort 5,Group 1: LDV/SOF + RBV 24 wk (SOF retreatment)

    LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HBV coinfection)

    LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection

    Drug: LDV/SOF

Interventions

  • DrugLDV/SOF

    Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily

    Also known as: Harvoni®, GS-5885/GS-7977

  • DrugSOF

    SOF 400 mg tablet administered orally once daily

    Also known as: GS-7977, Sovaldi®

  • DrugRBV

    Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

  • pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly

    Also known as: Pegasys®

  • GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily

  • DrugVEL

    Velpatasvir (VEL) tablet(s) administered orally once daily

    Also known as: GS-5816

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 is defined as HCV RNA \< lower limit of quantification (LLOQ) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants With Adverse Events Leading to Permanent Discontinuation of Study Drug(s)

    Time frame: Up to 24 weeks plus 30 days

Secondary outcomes

  1. Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment

    Time frame: Weeks 1 and 2

  2. Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment

    Time frame: Weeks 4, 6, and 8

  3. Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment

    Time frame: Week 10

  4. Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment

    Time frame: Week 12

  5. Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment

    Time frame: Weeks 16, 20, and 24

  6. Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR 24)

    Time frame: Posttreatment Weeks 2, 4, 8, and 24

  7. For Cohort 6, Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 16 and 20 Weeks After Discontinuation of Therapy (SVR16 and SVR 20)

    Time frame: Posttreatment Weeks 16 and 20

  8. Percentage of Participants With On-treatment Virologic Failure

    On-treatment virologic failure was defined as: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)

    Time frame: Up to Posttreatment Week 24

  9. Percentage of Participants Experiencing Viral Relapse

    Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.

    Time frame: Up to Posttreatment Week 24

07

Results

Posted Sep 16, 2016
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at a total of 2 study sites in New Zealand. The first participant was screened on 3 April 2016. The last study visit occurred on 25 May 2015.

Participant flow — Overall Study
MilestoneCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Started19102526252625512027242726208
Completed1992526182524401326222525158
Not completed0100711117122150
Withdrew: Lack of efficacy010050087010030
Withdrew: Lost to follow-up000011010111100
Withdrew: Withdrew consent000000110001010
Withdrew: Adverse event000010000000000
Withdrew: Upper g-i haemorrhage000000000000010
Withdrew: Enrolled/randomized but not treated000000010000000

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 is defined as HCV RNA \< lower limit of quantification (LLOQ) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)1009010010064.010096.082.065.010087.596.3100.075100
PrimaryPercentage of Participants With Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
Time frame:
Up to 24 weeks plus 30 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
Percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Percentage of Participants With Adverse Events Leading to Permanent Discontinuation of Study Drug(s)004.004.0002.0004.203.85.00
SecondaryPercentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame:
Weeks 1 and 2
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Week 115.830.04.011.520.011.512.012.0033.34.226.919.215.012.5
Week 263.250.044.053.864.061.556.052.025.070.466.765.469.245.075.0
SecondaryPercentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame:
Weeks 4, 6, and 8
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Week 4100.0100.084.092.395.888.596.096.075.096.395.792.396.275.087.5
Week 6100.0100.0100.0100.0100.0100.096.0100.0100.0100.0100.0100.0100.090.0100.0
Week 8100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.090.0100.0
SecondaryPercentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment100.0100.0100.0100.0100.0100.0100.098.0100.0100.0100.0
SecondaryPercentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment100.0100.0100.0100.0100.0100.0100.098.0100.0100.0100.0
SecondaryPercentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame:
Weeks 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
percentage of participantsCohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)
Week 16100.0
Week 20100.0
Week 24100.0
SecondaryPercentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR 24)
Time frame:
Posttreatment Weeks 2, 4, 8, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR 24)
percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
SVR2100.0100.0100.0100.072.0100.0100.090.095.0100.087.596.3100.095.0100.0
SVR4100.0100.084.092.395.888.596.096.075.096.395.792.396.275.087.5
SVR8100.090.0100.0100.064.0100.096.082.065.0100.087.596.3100.080.0100.0
SVR24100.090.0100.0100.064.0100.096.082.065.0100.087.596.3100.075.0100.0
SecondaryFor Cohort 6, Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 16 and 20 Weeks After Discontinuation of Therapy (SVR16 and SVR 20)
Time frame:
Posttreatment Weeks 16 and 20
Reported as:
Number · percentage of participants
For Cohort 6, Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 16 and 20 Weeks After Discontinuation of Therapy (SVR16 and SVR 20)
percentage of participantsCohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
SVR16100
SVR20100
SecondaryPercentage of Participants With On-treatment Virologic Failure

On-treatment virologic failure was defined as: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure
percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Percentage of Participants With On-treatment Virologic Failure000000000000000
SecondaryPercentage of Participants Experiencing Viral Relapse

Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Viral Relapse
percentage of participantsCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)
Percentage of Participants Experiencing Viral Relapse010.00033.304.016.335.008.70015.00

Adverse events

Collected over Up to 24 Weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)—0/19 (0%)17/19 (89.5%)
Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)—0/10 (0%)10/10 (100%)
Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)—1/25 (4%)24/25 (96%)
Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease—0/26 (0%)24/26 (92.3%)
Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)—4/25 (16%)24/25 (96%)
Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)—0/26 (0%)23/26 (88.5%)
Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)—1/25 (4%)21/25 (84%)
Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)—1/50 (2%)43/50 (86%)
Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)—2/20 (10%)19/20 (95%)
Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)—3/20 (15%)17/20 (85%)
Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)—0/8 (0%)6/8 (75%)
Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)—1/27 (3.7%)18/27 (66.7%)
Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)—0/24 (0%)18/24 (75%)
Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)—0/27 (0%)22/27 (81.5%)
Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)—0/26 (0%)21/26 (80.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)
Hepatic cirrhosisHepatobiliary disorders0/190/100/250/260/250/260/250/500/201/200/80/270/240/270/26
Lower respiratory tract infectionInfections and infestations0/190/100/250/260/250/260/250/500/201/200/80/270/240/270/26
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/190/100/250/260/250/260/250/500/201/200/80/270/240/270/26
Squamous cell carcinoma of the tongueNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/190/100/250/260/250/260/250/501/200/200/80/270/240/270/26
EncephalopathyNervous system disorders0/190/100/250/260/250/260/250/500/201/200/80/270/240/270/26
Acute kidney injuryRenal and urinary disorders0/190/100/250/260/250/260/250/501/200/200/80/270/240/270/26
Angina pectorisCardiac disorders0/190/101/250/260/250/260/250/500/200/200/80/270/240/270/26
Pericardial effusionCardiac disorders0/190/101/250/260/250/260/250/500/200/200/80/270/240/270/26
Choroidal effusionEye disorders0/190/100/250/261/250/260/250/500/200/200/80/270/240/270/26
Lens dislocationEye disorders0/190/100/250/261/250/260/250/500/200/200/80/270/240/270/26
Most frequent other events
Showing 10 of 131
Most frequent other events
EventCohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)
Viral infectionInfections and infestations0/190/104/250/260/250/262/251/500/201/205/80/270/241/270/26
NauseaGastrointestinal disorders4/193/107/2511/269/254/260/255/503/201/200/84/271/244/273/26
Upper respiratory tract infectionInfections and infestations4/191/108/255/269/259/266/259/508/206/202/81/273/243/274/26
HeadacheNervous system disorders5/192/1010/259/2610/258/262/2513/504/203/200/86/275/243/274/26
InsomniaPsychiatric disorders7/192/107/251/263/253/260/2510/503/201/200/80/273/246/272/26
FatigueGeneral disorders6/193/105/259/265/252/266/2513/504/204/202/85/273/244/277/26
ChillsGeneral disorders0/193/100/250/260/250/260/250/500/200/200/80/270/240/270/26
Lower respiratory tract infectionInfections and infestations0/190/100/252/262/252/260/252/500/206/200/80/270/241/270/26
ArthralgiaMusculoskeletal and connective tissue disorders2/193/100/250/260/252/260/251/501/200/200/80/270/241/271/26
RashSkin and subcutaneous tissue disorders4/192/100/252/261/251/262/257/501/203/200/80/273/242/274/26

Baseline characteristics

Safety analysis set: Participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Total
Mean55 ± 6.149 ± 12.556 ± 5.355 ± 6.743 ± 10.248 ± 9.251 ± 13.952 ± 8.256 ± 5.548 ± 7.947 ± 7.950 ± 10.247 ± 10.354 ± 7.053 ± 6.950.7 ± 9.44
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Total
Female62101112159113106101522124
Male1381515131116391717181711186234
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Total
White189222422233401720202019183278
Asian001011223110100132
Native Hawaiian or Other Pacific Islander01211105252361434
American Indian or Alaska Native0000000000001001
Other10011102012301013
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Total
Not Hispanic or Latino19102526252625502027242726208358
HCV Genotype
HCV Genotype(participants)Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Total
1b with possible mixed infection with Genotype 40010000000000001
Genotype 1a160152200001800009686
Genotype 1a with possible 6 (subtypes c - l)1000000000000001
Genotype 1b20940000200000219
Genotype 30000100302100007
Genotype 3a010002425046025222726100215
Genotype 3k0000000000100001
Genotype 6 (subtypes c - l)000000170000000017
Genotype 6a or 6b0000008000000008
Indeterminate genotype. Sequencing indicates GT3a0000000100000001
Indeterminate pattern. Sequencing indicates GT3k0000010000000001
Missing0000000000000101
Cirrhosis Status
Cirrhosis Status(participants)Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Total
No189792120232802724272666251
Yes11181746222200000142107
IL28b Status
IL28b Status(participants)Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Total
CC436491520187106151477145
CT125121910652761315111071159
TT32736505743126054
HCV RNA
HCV RNA(log 10 IU/mL)Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment)Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment)Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease)Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver DiseaseCohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B)Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic)Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic)Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment)Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection)Total
Median6.3 ± 0.516.5 ± 0.636.5 ± 0.396.1 ± 0.696.3 ± 0.886.3 ± 0.876.7 ± 0.676.3 ± 0.766.0 ± 0.485.9 ± 0.866.3 ± 0.696.0 ± 0.716.2 ± 0.926.0 ± 0.486.0 ± 10.96.2 ± 0.76

1 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Auckland Clinical Studies Ltd.
    Auckland, New Zealand
  • Christchurch Clinical Studies Trust
    Christchurch, New Zealand
09

References and documents

Publications

  • Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, Stedman CA. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015 Nov;149(6):1454-1461.e1. doi: 10.1053/j.gastro.2015.07.063. Epub 2015 Aug 7. PubMed 26261007 ↗
  • Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir Ther. 2016;21(7):605-609. doi: 10.3851/IMP3066. Epub 2016 Jul 1. PubMed 27367295 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Mar 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 1 year 6 months after primary completion. A results delay was requested in Jan 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2013
First posted
Apr 9, 2013
Start
Apr 2013
Primary completionActual
Mar 2015
CompletionActual
May 2015
Results delay requested
Jan 22, 2016
Results first posted
Sep 16, 2016
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01826981
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 9, 2013
Start date
Apr 2013
Primary completion
Mar 2015
Completion
May 2015
Results posted
Sep 16, 2016
Last update
Nov 16, 2018

Study contacts

Robert H Hyland, DPhil
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Ribavirin · Interferons · GS-9669 · Velpatasvir

Start the discussion